SCHEMBL4572542

SCHEMBL4572542

CC(C)(C)OC(=O)NCCCCCN1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.60
TDP1 Q9NUW8 1/20 0.59
CHRM2 P08172 2/20 0.54
CHRM4 P08173 2/20 0.54
CHRM5 P08912 2/20 0.54
CHRM1 P11229 2/20 0.54
CHRM3 P20309 2/20 0.54
MAOA P21397 1/20 0.52
MAOB P27338 1/20 0.52
ACHE P22303 1/20 0.51
BACE1 P56817 1/20 0.51
SIGMAR1 Q99720 2/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31596990 0.97 DRD2 (0.58) DRD2TDP1CHRM2CHRM4CHRM5
SCHEMBL3524057 0.94 DRD2 (0.66) DRD2TDP1MAOAMAOBSIGMAR1
Iodide SCHEMBL15145961 0.92 DRD2 (0.57) DRD2TDP1CHRM2CHRM4CHRM5
SCHEMBL4743239 0.92 ACHE (0.58) DRD2TDP1CHRM2CHRM4CHRM5
SCHEMBL30572390 0.90 DRD2 (0.57) DRD2TDP1CHRM2CHRM4CHRM5
SCHEMBL29263630 0.90 DRD2 (0.62) DRD2TDP1MAOAMAOBSIGMAR1
SCHEMBL9127008 0.89 DRD2 (0.60) DRD2TDP1ACHEBACE1SIGMAR1
SCHEMBL8254760 0.87 DRD2 (0.64) DRD2TDP1SIGMAR1MEN1GAA
SCHEMBL4024516 0.87 DRD2 (0.56) DRD2TDP1CHRM2CHRM4CHRM5
SCHEMBL24913972 0.87 DRD2 (0.57) DRD2TDP1MAOAMAOBSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142518-B1 3,4-DIHYDROQUINAZOLINE DERIVATIVES DONGWOO SYNTECH CO LTD (KR) 2012-05-02 EP disclosed
US-8168646-B2 3,4-dihydroquinazoline derivatives DONGWOO SYNTECH CO., LTD. (KR) 2012-05-01 US disclosed
US-8168646-B2 3,4-dihydroquinazoline derivatives DONGWOO SYNTECH CO., LTD. (KR) 2012-05-01 US disclosed
US-20100120803-A1 3,4-DIHYDROQUINAZOLINE DERIVATIVES DONGWOO SYNTECH CO., LTD. (KR) 2010-05-13 US disclosed
US-20100120803-A1 3,4-DIHYDROQUINAZOLINE DERIVATIVES DONGWOO SYNTECH CO., LTD. (KR) 2010-05-13 US disclosed
WO-2008136631-A1 3,4-DIHYDROQUINAZOLINE DERIVATIVES DONGWOO SYNTECH CO., LTD. (KR) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120803-A1 3,4-DIHYDROQUINAZOLINE DERIVATIVES CACNA1I, CACNA1G, CACNA1H DRD2 543/4885TDP1 2210/4885CHRM2 2244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.